TABLE 2.
Number of DLA solutions currently available
| Approving body | Design | Target disease | Sensitivity/specificity | |
|---|---|---|---|---|
| DR Grader 31 | TGA | CFP | DR | −/92% |
| EyeArt 32 | FDA, CE | CFP |
DR MD GL |
92%/92% 90%/70% 90%/93% |
| Eyetelligence 33 , 34 , 35 | TGA |
CFP OCT |
DR MD GL |
92%/94% 100%/93% 96%/92% |
| IDx‐DR 36 | FDA, CE | CFP | DR | 87%/91% |
| Retinalyze 37 , 38 | CE | CFP, OCT |
DR GL |
90%/86% 76%/99% |
| DeepMind 39 | Research verified | OCT | DR | 96%/93% |
| RetCAD 40 , 41 | CE | CFP |
DR MD |
91%/97% 92%/86% |
| Retmarker 42 | CE | CFP | DR | 97%/88% |
Abbreviations: CE, Conformitè Europëenne; CFP, Colour Fundus Photography; FDA, Federal Drug Administration; OCT, Optical Coherence Tomography; TGA, Therapeutic Goods Administration.
Source: Chia MA, Turner AW. Benefits of Integrating Telemedicine and Artificial Intelligence Into Outreach Eye Care: Stepwise Approach and Future Directions. Frontiers in Medicine. 20